Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

146.16 -1.59 (-1.08%)
Streaming Delayed Price Updated: 1:58 PM EST, Feb 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
29 30 Next >
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE: 
Via Benzinga
Should You Buy This Blue Chip Biotech Stock?
AbbVie may be able to provide relief to the income investor struggling to find sanely valued stocks with safe dividends. 
Via The Motley Fool
Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3
Warren Buffett's Berkshire Hathaway Inc (NYSE: BRK-A) cleared its stake in Merck & Co Inc (NYSE: MRK) in Q3, right on the eve of a significant stock... 
Via Benzinga
Europe Approves AbbVie's Skyrizi For Second Indication
The European Commission (EC) has approved AbbVie Inc's (NYSE: ABBV) Skyrizi (risankizumab) 150 mg subcutaneous injection for psoriatic arthritis in adults. The... 
Via Benzinga
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea... 
Via Benzinga
1 Dividend Stock to Help You Fight Inflation
We'll need this company's products long after the current inflation crisis ends. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
Via Investor's Business Daily
Turbo Dividend – This Stock Pays A High-yield Of 5.5% And Pays Out Monthly
Today, I want to tell you about six dividend growth stocks that just increased their dividends. 
Via Talk Markets
Merck Is a Dividend Play Ready to Get Back in Gear
Pfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead. 
Via InvestorPlace
Exposures COVID-19
Warren Buffett Stocks: Berkshire Hathaway To Reveal Q3 Stock Buys And Sells
Berkshire Hathaway will file its 13-F, detailing changes to its stock holdings. 
Via Investor's Business Daily
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash
AbbVie and Gilead Sciences are two top high-yield stocks that could save your portfolio in the event of a marketwide downturn. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
Photo by Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
5 Dividend Increases Expected In November 2021
We are off to the races in the eleventh month of this year. 2021 has been a fantastic year for dividend investors as companies have been announcing stronger-than-expected dividend increases. Let’s see... 
Via Talk Markets
Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More
This weekend's Barron's cover story examines the bubbles in cryptocurrency, meme stocks and non-fungible tokens. Other featured articles discuss the stocks powering 2021... 
Via Benzinga
Merck Receives Another Boost for Its Top-Selling Drug
The company announced it has received approval for another Keytruda indication in the E.U. 
Via The Motley Fool
7 Dividend Aristocrat Stocks That Should Grace Your Portfolio
You get a lot more more from dividend aristocrat stocks than just a rock-solid dividend. They also promise solid, long-term growth. 
Via InvestorPlace
Topics Economy
Exposures Economy
Clinical-Stage Biopharmaceutical Company HOTH Says It Is on a Mission to Develop Next-Generation Therapeutics to Meet Patient Needs
Photo by Roberto Sorin on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Why Teva Pharmaceutical Stock Is Jumping Today
The company won in a California opioid-related lawsuit. 
Via The Motley Fool
Healthcare Stocks Subject to Government Policy
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the... 
Via Benzinga
Topics Stocks
Exposures US Equities
California Judge Rules For Drugmakers In Major Opioid Litigation
A California judge cleared four drugmakers of liability, accusing the companies of causing widespread opioid addiction in the state. Teva Pharmaceuticals Industries Ltd... 
Via Benzinga
Crypto Punk Sets The NFT World On Fire
“Crypto Punk”, a Non-Fungible Token (NFT), sold for a stunning $532 million, setting yet another high water mark for this odd asset class. 
Via Talk Markets
AbbVie (ABBV) Q3 2021 Earnings Call Transcript
ABBV earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why AbbVie Shares Are Rising Today
AbbVie Inc (NYSE: ABBV) is trading higher Friday after the company announced better-than-expected third-quarter financial results and raised guidance above estimates. AbbVie... 
Via Benzinga
AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials
AbbVie Inc (NYSE: ABBV) has announced topline results from two Phase 3 trials, Study 3111-301-001 and Study 3111-302-001, of cariprazine (Vraylar) as an adjunctive... 
Via Benzinga
AbbVie Stock Nears Breakout After Topping Forecasts As Botox Sales Rocket
AbbVie stock inched higher Friday after the company beat third-quarter forecasts. 
Via Investor's Business Daily
AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend
AbbVie Inc (NYSE: ABBV) reports Q3 adjusted EPS of $3.33, higher than $2.83 reported a year ago and beating the consensus of $3.22. Overall sales increased 11.2% Y/Y to... 
Via Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Earnings Scheduled For October 29, 2021
Companies Reporting Before The Bell • Sify Technologies (NASDAQ:SIFY) is expected to report quarterly earnings at $0.02 per share on revenue of $97.70 million. •... 
Via Benzinga
FDA Restricts Sale, Approves New Labeling Of Breast Implants
The FDA is restricting the sale and distribution of breast implants over concerns about the risks of the devices, limiting the products to healthcare providers and... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.